Patents by Inventor Mark S. Dennis

Mark S. Dennis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11466087
    Abstract: The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: October 11, 2022
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Steven R. Leong, Wei-Ching Liang, Mary Mathieu, Andrew G. Polson, Bing Zheng, Xiaocheng Chen, Cecilia Pui Chi Chiu, Mark S. Dennis, Allen Ebens, Yan Wu
  • Patent number: 11370832
    Abstract: In one aspect, antibodies that specifically bind to a human Tau protein are provided. In some embodiments, an anti-Tau antibody recognizes an epitope within residues 111-125 of full-length human Tau, an epitope within residues 251-270 and/or residues 346-360 of full-length human Tau, or an epitope within residues 186-205 of full-length human Tau. In some embodiments, an anti-Tau antibody specifically binds to phosphorylated human Tau, unphosphorylated human Tau, and/or multiple splice isoforms of human Tau. An anti-Tau antibody disclosed herein may also include one or two modified Fc polypeptides.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: June 28, 2022
    Assignee: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Lesley Ann Kane, Do Jin Kim, Joseph W. Lewcock, Suresh Poda, Rishi Rakhit, Rinkan Shukla, Adam P. Silverman
  • Publication number: 20220177576
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Application
    Filed: September 17, 2021
    Publication date: June 9, 2022
    Inventors: Mark S. Dennis, Zhenyu Gu, Mihalis Kariolis, Cathal Mahon, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Adam P. Silverman, Bettina Van Lengerich
  • Publication number: 20220119522
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Application
    Filed: August 16, 2021
    Publication date: April 21, 2022
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Sherie Duncan, Kathleen Lisaingo, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Ju Shi, Ankita Srivastava, Bettina Van Lengerich, Riley Walsh
  • Publication number: 20220073609
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Application
    Filed: August 16, 2021
    Publication date: March 10, 2022
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Sherie Duncan, Kathleen Lisaingo, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Ju Shi, Ankita Srivastava, Bettina Van Lengerich, Riley Walsh
  • Publication number: 20220002436
    Abstract: The present disclosure relates to anti-HER2 constructs, such as Fc polypeptide dimer-antibody variable region fusion proteins, that cross the BBB and bind to HER2 in the brain parenchyma. In some embodiments, the anti-HER2 constructs (e.g., Fc polypeptide dimer-antibody variable region fusion proteins) retain effector function upon binding to HER2, but do not substantially deplete reticulocytes in vivo. The present disclosure also relates to methods for transcytosing an anti-HER2 antibody variable region across the BBB and treating HER2-positive cancers and metastatic lesions thereof.
    Type: Application
    Filed: February 18, 2021
    Publication date: January 6, 2022
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Wanda Kwan, Joseph W. Lewcock, Jonathan Sockolosky, Joy Yu Zuchero
  • Patent number: 11186650
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: November 30, 2021
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Allen J. Ebens, Jr., Robert F. Kelley, Mary A. Mathieu, Liping L. Sun
  • Patent number: 11124562
    Abstract: The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of A plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: September 21, 2021
    Assignee: Washington University
    Inventors: David Holtzman, Hong Jiang, Fan Liao, Thu Nga Bien-Ly, Mark S. Dennis, Jing Guo, Adam P. Silverman, Ryan J. Watts, Yin Zhang
  • Patent number: 11124567
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: September 21, 2021
    Assignee: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Zhenyu Gu, Mihalis S. Kariolis, Cathal S. Mahon, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Adam P. Silverman, Bettina Van Lengerich
  • Patent number: 11098129
    Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: August 24, 2021
    Assignee: Genentech, Inc.
    Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S Dennis, James A Ernst, Ryan J Watts, Gregory A Lazar
  • Publication number: 20210244815
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Application
    Filed: April 14, 2021
    Publication date: August 12, 2021
    Inventors: Chingwei Vivian LEE, Mark S. DENNIS, Germaine FUH
  • Publication number: 20210214438
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Application
    Filed: January 15, 2021
    Publication date: July 15, 2021
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Zhenyu Gu, Mihalis S. Kariolis, Cathal S. Mahon, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Adam P. Silverman, Bettina Van Lengerich
  • Publication number: 20210198640
    Abstract: Provided herein are fusion proteins that comprise an enzyme replacement therapy enzyme and an Fc region, as well as methods of using such proteins to treat a lysosomal storage disorder. Methods for transporting agents across the blood-brain barrier are also provided herein.
    Type: Application
    Filed: November 23, 2020
    Publication date: July 1, 2021
    Applicant: Denali Therapeutics Inc.
    Inventors: Giuseppe Astarita, Mark S. Dennis, Jennifer A. Getz, Anastasia Henry, Mihalis Kariolis, Cathal Mahon, Adam P. Silverman, Ankita Srivastava, Julie Ullman, Junhua Wang, Joy Yu Zuchero
  • Patent number: 11007267
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: May 18, 2021
    Assignee: Genentech, Inc.
    Inventors: Chingwei Vivian Lee, Mark S. Dennis, Germaine Fuh
  • Patent number: 11008403
    Abstract: The present invention relates to bispecific antibodies that bind to transferrin receptor and BACE1 and methods of using the same.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: May 18, 2021
    Assignees: Genentech, Inc., Adimab LLC
    Inventors: Yichin Liu, Jasvinder Atwal, Cecilia Pui Chi Chiu, Ryan J. Watts, Yan Wu, Eric Krauland, Michael Feldhaus, Yin Zhang, Joy Yu Zuchero, Jessica Couch, Mark S Dennis, James A Ernst, Gregory A Lazar
  • Publication number: 20210130485
    Abstract: The present disclosure relates generally to Fc polypeptide dimers that contain a non-native transferrin receptor (TfR) binding site, do not substantially deplete reticulocytes in vivo, but retain binding to the Fc? receptor (Fc?R). The present disclosure also relates to an Fc polypeptide dimer that contains a non-native site that specifically binds TfR on one of the Fc polypeptides; a modification or modifications on the Fc polypeptide containing the TfR-binding site that reduces Fc?R binding when bound to TfR, where the other Fc polypeptide does not contain a TfR-binding site but retains Fc?R binding.
    Type: Application
    Filed: July 6, 2020
    Publication date: May 6, 2021
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Mihalis Kariolis, Wanda Kwan, Adam P. Silverman, Zachary K. Sweeney, Joy Yu Zuchero
  • Publication number: 20210087288
    Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.
    Type: Application
    Filed: September 1, 2020
    Publication date: March 25, 2021
    Applicant: Genentech, Inc.
    Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S. Dennis, James A. Ernst, Ryan J. Watts, Gregory A. Lazar
  • Publication number: 20210070881
    Abstract: In one aspect, antibodies that specifically bind to a human BACE1 protein are provided herein. In some embodiments, the antibodies contain modifications that reduce effector function, extend serum stability or serum half-life, or promote heterodimerization. In other aspects, bispecific antibodies and pharmaceutical compositions comprising antibodies that bind to human BACE1 protein are provided herein. Methods for inhibiting amyloid-? formation and/or aggregation, inhibiting amyloid plaque formation, and treating neurodegenerative diseases are also provided herein.
    Type: Application
    Filed: May 6, 2020
    Publication date: March 11, 2021
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Jennifer A. Getz, Rinkan Shukla, Adam P. Silverman, Yin Zhang, Joy Yu Zuchero
  • Patent number: 10941199
    Abstract: The invention provides anti-CD79b antibodies and methods of using the same.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: March 9, 2021
    Assignee: Genentech, Inc.
    Inventors: Liping L. Sun, Yvonne Man-Yee Chen, Mark S. Dennis, Allen J. Ebens, Jr., Andrew Polson
  • Patent number: 10865251
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: December 15, 2020
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Allen J. Ebens, Jr., Robert F. Kelley, Mary A. Mathieu, Liping L. Sun